Jeffreys Henry, the award-winning provider of audit, tax and advisory services to LSE, AIM and Aquis listed companies, has advised Aptamer Group Plc on its £80.7 million AIM IPO.

‍British biotechnology firm Aptamer Group is a leader in the provision of aptamer discovery and development services using its proprietary automated and high-throughput Optimer® platform. The company operates across three life science sectors: custom services (research and bioprocessing tools), diagnostics and therapeutics.

Over the past four years, Aptamer Group has seen organic revenue growth of 400% and developed a blue-chip customer base, having supplied or collaborated with 75% of the global top 20 pharmaceutical companies.

On Admission, the market capitalisation of Aptamer Group was approximately £80.7 million. The Placing raised gross proceeds of £10.8 million and attracted strong support from high-quality institutional investors.

This marks the latest of a string of IPOs supported by Jeffreys Henry’s specialist Capital Markets team. Previously, Jeffreys Henry advised Mode Global Holdings Plc on its £40.3m IPO, and Technology Minerals Plc on its £27.3m IPO.